SynthesisFrontiers in cellular and infection microbiology2025
Prevalence of enterotoxigenic
Synthesis in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Bacteroides fragilis toxin promotes gall bladder cancer in mice.Nature microbiology · 2026Article
- Gut Microbiome-Driven Strategies to Overcome Immunotherapy Resistance in Microsatellite-Stable Colorectal Cancer.Cancers · 2026Review
- Features of the Intestinal and Respiratory Microbiome in Colorectal Cancer Patients in Western Siberia.Microorganisms · 2026Article
- Synbiotics as a Microbiome-Based Strategy in Colorectal Cancer.Nutrients · 2026Review
- Gut Microbiota-Non-Coding RNA Axis in Immune Modulation and Disease: From Mechanisms to Clinical Translation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The gut microbiome in colorectal cancer: mechanisms of carcinogenesis and emerging microbiota-targeted therapies.Discover oncology · 2026Review
- The microbiota-metabolite-immune axis in colorectal cancer: mechanistic insights and emerging clinical applications.Frontiers in immunology · 2026Review
- Virulome over taxonomy: refining the driver-passenger model in colorectal carcinogenesis.Frontiers in cellular and infection microbiology · 2026Review
- Emerging risk factors and the role of gut microbiota in immunomodulation and therapeutic implications in colorectal cancer.Cancer pathogenesis and therapy · 2026Review
- Tumor-Promoting Gut Microbes in Colorectal Cancer: Mechanisms and Translational Perspectives.International journal of medical sciences · 2026Review
- Applying principles of vaccine development to oncomicrobial vaccines.Blood advances · 2025Review
- The Ambivalent Nature ofToxins · 2025Review
- The Knowledge Gap in Gut Microbiome Characterization in Early-Onset Colorectal Cancer Patients: A Systematic Scoping Review.Cancers · 2025Review
- Inflammatory Bowel Disease Mediates the Causal Relationship Between Gut Microbiota and Colorectal Cancer: Identification of Therapeutic Targets and Predictive Modeling.Journal of Cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The gut microbiome, specifically enterotoxigenic Methods: PubMed, EMBASE, and The Cochrane Library were systematically searched for studies published until May 2024. We utilized studies either comparing the prevalence of ETBF in patients with colorectal cancer and healthy control or examining its prevalence across different stages of colorectal cancer. The prevalence of ETBF colonization in biological samples from individuals with colorectal cancer compared to that in healthy controls or adjacent normal tissue as well as the association between the prevalence of ETBF and various stages of colorectal cancer were plotted using a random-effect or fixed-effect model. Results: Fourteen relevant articles were identified. Meta-analyses revealed that patients with colorectal cancer had a higher likelihood of having ETBF than healthy controls (odds ratio [OR]: 2.54, 95% confidence interval [CI]: 1.63-3.98, I Discussion: The prevalence of ETBF was consistently higher in the tissue and fecal samples of patients with colorectal cancer than in those of controls. A difference in ETBF prevalence between stage I/II and stage III/IV colorectal cancer was noted, but further analysis revealed that the conclusion is unreliable. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD 42024548325.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.